gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · HALOHealthcareBiotechnology

Halozyme Therapeutics, Inc. (HALO)

$130.34+1.34%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$129.42▲ 95.50% in range
Nov 3, 2025Low $61.63 · High $131.18Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Halozyme Therapeutics closed at $130.34 on Nov 4, up 1.34%, 0.6% below its 52-week closing high. Volume of 1.6M shares was 0.74× its 20-day average (below normal).

Split-adjusted performance: +18.8% over one month, +96.4% over six months, +96.9% over one year.

In the quarter ended Jun 30, 2026, revenue was $481M, up 47.7% from a year earlier, with a net margin of 47.8%.

Short interest was 13.7M shares at the Oct 15 settlement, down 10.7% from the prior report (12.4% of float, 6.2 days to cover).

Market cap$14.79B113.5M shares
Revenue · quarter$481.0M+47.7% YoY
Diluted EPS$1.90+42.9% YoY
P/E · TTM35.8×P/S 8.9×
Net margin47.8%Gross 83.5%
Dividend yieldNone
52-week range61.63 – 131.18−0.6% from high
Volume1.6M0.74× 20-day avg
Volatility · 60d27.9%Annualised
Short % of float12.4%6.2 days to cover
Net cash-$1.92BCash $231.0M
Next earnings—Not scheduled
Split-adjusted performance
1W +0.2%1M +18.8%3M +52.0%6M +96.4%YTD +93.7%1Y +96.9%3Y +283.4%5Y +248.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum95
Revenue growth78
Net margin93
Value (low P/E)31
Size95

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short13.7M−10.7% vs prior
Days to cover6.2Settled Oct 15
% of float12.4%
Short vol. 10d54.6%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
HALOHalozyme Therapeutics$130.34+1.34%+96.4%+47.7%47.8%35.8$14.79B
NBIXNeurocrine Biosciences$166.05+0.73%+12.9%+41.2%18.4%24.0$16.88BCompare
EXELExelixis$72.75+0.61%+49.4%+10.2%33.1%20.1$17.75BCompare
KYMRKymera Therapeutics$136.25+7.21%+58.0%−100.0%——$11.63BCompare
TECHBio-Techne$72.73+0.10%+53.4%+1.3%17.0%62.8$11.42BCompare
RGENRepligen$178.20−0.04%+41.7%+10.9%−18.4%—$11.31BCompare
PCVXVaxcyte$65.68+8.01%+15.0%———$10.34BCompare
IBRXImmunityBio$8.93+7.72%+6.6%+93.9%−449.6%—$9.46BCompare
TWSTTwist Bioscience$142.58+1.63%+139.5%+23.2%−29.6%—$9.45BCompare

News about Halozyme Therapeutics

All news →
The Zacks Analyst Blog Highlights Chord Energy, Halozyme, Sezzle, SanDisk and TeradyneZacks Investment Research · Oct 22, 2026▲ PositiveZacks.com featured highlights include Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions, Permian Resources and ChevronZacks Investment Research · Oct 19, 2026▲ PositiveThe Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme TherapeuticsZacks Investment Research · Oct 19, 2026▲ PositiveHere's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth TodayZacks Investment Research · Oct 15, 2026▲ Positive3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)Zacks Investment Research · Oct 14, 2026▲ Positive

Quick answers

What does Halozyme Therapeutics do?
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors.
What is HALO's market cap?
$14.79B, based on the Nov 4 close of $130.34.
What is HALO's P/E ratio?
35.8× trailing-twelve-month earnings of $413.60M.
Does Halozyme Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of HALO is sold short?
13.7M shares, 12.4% of float, as of Oct 15, 2026.
What sector is HALO in?
Healthcare, in the Biotechnology industry.

About Halozyme Therapeutics

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

HQ: San Diego, CA423 employeesListed Mar 12, 2004halozyme.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology